Thr62
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr62  -  GRB7 (human)

Site Information
REEERRAtSLPsIPN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 50323666
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 )
Disease tissue studied:
breast cancer ( 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
lapatinib ( 2 )

References 

1

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

2

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info